Join Kyle George, PA-C, a practicing physician assistant in Idaho, as he answers a frequently asked question: How does axial psoriatic arthritis (Axial PsA) differ from ankylosing spondylitis (AS) in clinical presentation, genetic associations, and radiographic findings?

This session delves into critical distinctions between these conditions, including differences in joint involvement, disease progression, and imaging patterns. Genetic markers such as HLA associations and cytokine pathways—including IL-17A, TNF, and IL-10—are explored to better understand their roles in axial disease. Additionally, insights from post hoc analysis of the DISCOVER-1 and DISCOVER-2 trials highlight the efficacy of Guselkumab (Tremfya) in Axial PsA, demonstrating significant improvements in BASDAI scores, spinal pain reduction, and ASDAS response rates.

Understanding the nuances between Axial PsA and AS is crucial for optimizing patient care, selecting appropriate therapies, and improving long-term disease outcomes.

For expert insights on psoriatic arthritis, axial disease, and the latest treatment advances, visit the RhAPP website or explore additional educational content on the RhAPP ACE App.